What are the recommended doses of meropenem, teicoplanin, and polymyxin B for an anuric patient receiving alternate‑day hemodialysis?

Dosing Recommendations for Anuric Patients on Alternate-Day Hemodialysis

For an anuric patient on alternate-day hemodialysis, administer meropenem 500 mg every 24 hours (half the standard dose), teicoplanin 800 mg loading dose followed by 400 mg every 5-7 days, and polymyxin B 150 mg loading dose followed by 75 mg every 12 hours, with all doses given after dialysis on dialysis days.

Meropenem Dosing

The FDA label explicitly states that for patients with creatinine clearance <10 mL/min (which includes anuric patients), the dose should be one-half the recommended dose every 24 hours 1. However, the label also notes "inadequate information regarding the use of meropenem in patients on hemodialysis" 1.

• Standard approach: For complicated intra-abdominal infections, this translates to 500 mg every 24 hours (half of the standard 1 gram dose)
• For complicated skin/soft tissue infections: 250 mg every 24 hours (half of 500 mg)
• Critical consideration: Recent simulation data suggests this may be inadequate for 3-day interdialytic periods, particularly for Pseudomonas infections 2

Timing: Administer immediately after hemodialysis on dialysis days to prevent premature drug removal 1. Meropenem is significantly cleared by hemodialysis.

Important caveat: The FDA dosing may be suboptimal for severe infections. Recent Monte Carlo simulations demonstrate that even 2 gram post-HD dosing fails to maintain adequate drug levels through a 3-day interdialytic period 2. For serious infections, consider therapeutic drug monitoring if available, or daily dosing of 500 mg-1000 mg depending on infection severity 3.

Teicoplanin Dosing

Teicoplanin has a long half-life and minimal dialysis clearance, making it particularly suitable for alternate-day hemodialysis patients 4.

For severe infections (e.g., MRSA bacteremia):

• Loading dose: 800 mg on day 1
• Maintenance: 400 mg on days 2,3,5,12, and 19 5
• This translates to approximately 400 mg every 5-7 days after the initial loading period

For minor infections:

• Loading dose: 800 mg initially
• Maintenance: 400 mg at weekly intervals 5

Key advantage: The Surviving Sepsis Campaign guidelines emphasize that loading doses of drugs with low volumes of distribution (including teicoplanin) are essential in critically ill patients to rapidly achieve therapeutic levels 4. The loading dose is not affected by renal function 4.

High-dose consideration: For severe disease or settings with elevated glycopeptide MICs, consider 12 mg/kg loading doses 6.

Polymyxin B Dosing

Polymyxin B has minimal renal clearance and is not significantly removed by hemodialysis 6, 7, making dose adjustment less critical than with other antibiotics.

Recommended regimen:

• Loading dose: 150 mg IV (or 2.5 mg/kg) as a single dose 8
• Maintenance dose: 75 mg every 12 hours 8

Rationale: Recent population pharmacokinetic data demonstrates that fixed-dose strategies (150-200 mg loading, then 75 mg q12h) achieve optimal target attainment while minimizing nephrotoxicity risk in patients weighing 50-90 kg 8. This challenges traditional weight-based dosing recommendations.

Alternative weight-based approach (from guidelines):

• Loading: 5 mg/kg IV × 1 dose
• Maintenance: 2.5 mg × (1.5 × CrCl + 30) IV q12h 9, 6
• For anuric patients (CrCl = 0): This simplifies to 2.5 mg × 30 = 75 mg every 12 hours

Critical safety note: Polymyxin B carries significant nephrotoxicity risk. The fixed-dose strategy may offer better safety-efficacy balance than weight-based dosing 8. Therapeutic drug monitoring is recommended when available 7.

General Principles for Alternate-Day Hemodialysis

1. Post-dialysis administration: All three antibiotics should be given immediately after hemodialysis on dialysis days to prevent premature removal and facilitate directly observed therapy 10, 11, 10

2. Loading doses are essential: In critically ill patients, always use full loading doses regardless of renal function to rapidly achieve therapeutic levels 4

3. Therapeutic drug monitoring: Strongly consider TDM for all three agents when available, particularly for:

   • Meropenem in severe infections 2, 3
   • Teicoplanin to ensure adequate trough levels
   • Polymyxin B to optimize efficacy and minimize toxicity 7, 8

4. Interdialytic period challenge: The 3-day interdialytic period (between weekend dialysis sessions) is particularly problematic for drugs with shorter half-lives like meropenem 2

Common Pitfalls to Avoid

• Underdosing meropenem: The FDA-recommended dose may be inadequate for serious infections, particularly Pseudomonas
• Omitting loading doses: This is a critical error in septic patients that delays therapeutic levels
• Weight-based polymyxin dosing without consideration of toxicity: Fixed dosing may be safer
• Administering drugs before dialysis: This wastes medication and risks subtherapeutic levels
• Ignoring the 3-day interdialytic gap: Standard dosing may fail during this period